Does Neoadjuvant Chemoimmunotherapy Boost Survival in NSCLC?

A meta-analysis confirms that neoadjuvant chemoimmunotherapy improves survival outcomes in most patients with resectable NSCLC, except for overall survival in patients with baseline PD-L1 below 1%.

Related Keywords

Quebec , Canada , Mark Sorin , Mcgill University , Morris Goodman Cancer Institute , European Medicines Agency , Drug Administration , European Medicines , Non Small Cell Lung Cancer , Nsclc , Lung Cancer , Ung Carcinoma , Ancer Of The Lung , Neoadjuvant , Meta Analysis , Chemotherapy , Small Cell Lung Cancer , At Cell Lung Cancer , Clc , Biologic Therapy , Iologics , Toxicology , Toxicity , Poisoning , Toxins , Cancer , Alignant Neoplasia , Arcinoma , Alignant Neoplasm , Europe , European , Tumor , Us Food And Drug Administration ,